‘Sputnik V’ COVID Vaccine Gets Approval for Clinical Trials in India

Russian Vaccine Sputnik V Has Been Approved for Second and Third Phase Testing

Sputnik V
Sputnik V Vaccine for COVID-19 is all set for the second and third phase of clinical testing in India. Pixabay

The Drug Controller General of India (DCGI) has granted approval to Dr. Reddy’s, a global pharmaceutical company headquartered in India, to conduct phase 2 and 3 clinical human trials of the Sputnik V, a COVID-19 vaccine made by Russia.

On September 16, the Russian Direct Investment Fund (RDIF) and Dr. Reddy’s Laboratories Limited had agreed to cooperate on clinical trials and distribution of the Sputnik V COVID-19 vaccine in India.

Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.

Follow NewsGram on LinkedIn to know what’s happening around the world.

Co-chairman and Managing Director of Dr. Reddy’s Laboratories G.V. Prasad in a statement said “This is a significant development that allows us to commence the clinical trials in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic.”

Sputnik V
The Drug Controller General of India (DCGI) has granted approval to Dr. Reddy’s, a global pharmaceutical company headquartered in India to Sputnik V made by Russia. Pixabay

“On regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on a well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic,” a statement from the Russian fund had earlier stated.

Also Read: Scientists Develop New Blood Test to Predict Which Covid-19 Patients at Severe Risk

The Russian Direct Investment Fund had also said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.

“The agreement between RDIF and Dr. Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations,” RDIF added. (IANS)